ACXPHealthcare · BiotechnologyThe 3 Wall Street analysts covering Acurx Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +861.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Acurx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Momentum (12): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ACXP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +861.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 12 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2025 | HC Wainwright & Co. | Assumes | Buy | $8.00 |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Dec 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ACXP appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Acurx Pharmaceuticals, Inc. returned −79.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 80% of US stocks
Cheaper than 59% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 11% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Acurx Pharmaceuticals, Inc. has a market value of $5.7M and an enterprise value of −$5.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$7.5M.
Free cash flow in the twelve months to 30 June 2026: −$6.2M.
Trailing P/E: −0.2×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Acurx Pharmaceuticals, Inc. employs 4 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Acurx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Acurx Pharmaceuticals said it will discuss its third-quarter 2026 financial results on a conference call scheduled for November 12, 2026, at 8:00 a.m. ET, before U.S. markets open.
Why it matters — ACXP watchers can note the scheduled call as an opportunity to hear the company’s quarterly results and business update.
Acurx announced publication in ASM’s Microbiology Spectrum of a study comparing gut microbiome effects of oral preclinical PolC inhibitors with linezolid in a murine infection model. The three tested inhibitors reduced MRSA burden while maintaining microbial diversity and metabolic function, unlike the disruption reported with linezolid.
Why it matters — The publication reports preclinical findings on Acurx’s antibiotic candidates, including microbiome effects and activity against MRSA.
Acurx Pharmaceuticals announced that the first patient has been enrolled in PATHFINDER, a Phase 2 clinical trial of ibezapolstat in patients with multiply-recurrent C. difficile infection. Results from the trial, along with the planned ASPIRE Phase 3 study in acute CDI, may inform a future active-controlled Phase 3 registration trial in rCDI.
Why it matters — This marks progress in advancing ibezapolstat's clinical development toward a potential single-agent treatment for recurrent C. difficile infection, which could shift how such infections are managed.
Acurx announced the presentation of a scientific poster at ICSD demonstrating superior in vitro kill kinetics of ibezapolstat. The study evaluated ibezapolstat, vancomycin, and fidaxomicin against C. difficile and Enterococcus in standalone and co-culture environments, finding that Enterococcus creates a protective microenvironment that impairs C. difficile treatment.
Why it matters — ACXP watchers would care because the data highlights ibezapolstat's potential advantage against C. difficile in complex infection environments, a key area for the company's lead candidate.
Acurx Pharmaceuticals announced that its proposed brand name, CIFBEZY, for its lead product candidate ibezapolstat received conditional acceptance from the FDA and federal trademark allowance from the USPTO. These initial milestones are intended to form the basis for the product's commercial identity as the company advances ibezapolstat toward its international Phase 3 registration program for both acute treatment and reduction of recurrence in C. difficile infection, with final FDA review of the name to be submitted at the time of the NDA marketing application.
Why it matters — The FDA conditional acceptance and USPTO trademark allowance represent early regulatory progress on the commercial identity of Acurx's lead candidate, ibezapolstat, as it moves toward its Phase 3 program for C. difficile infection.
The 3 Wall Street analysts covering Acurx Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Acurx Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acurx Pharmaceuticals, Inc. 25 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Acurx Pharmaceuticals, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +861.5% from the last close, and Ticker Nerd's factor model ranks Acurx Pharmaceuticals, Inc. 25 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Acurx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $31 over the next 12 months.
Acurx Pharmaceuticals, Inc. returned -79.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections.
The most recent item we track (PRNewsWire, 26 Oct 2026): "Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update". Acurx Pharmaceuticals said it will discuss its third-quarter 2026 financial results on a conference call scheduled for November 12, 2026, at 8:00 a.m. ET, before U.S. markets open.
Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for difficult-to-treat bacterial infections. Acurx Pharmaceuticals Inc. develops small-molecule therapies designed to target Gram-positive pathogens through a distinct mechanism of action, with its lead candidate ibezapolstat aimed at infections such as Clostridium difficile. The company is also advancing ACX-375C, an antibiotic program intended to address resistant bacteria including MRSA, VRE, and drug-resistant Streptococcus pneumoniae. In addition to its lead and pipeline candidates, Acurx Pharmaceuticals Inc. works on anti-infective therapies for pathogens identified as priority threats by major public health agencies. The company operates in the biopharmaceutical sector, where its research is centered on unmet medical needs in infectious disease treatment and the development of new options for antibiotic-resistant infections.
CEO Mr. David P. Luci CPA, Esq., J.D. · 4 employees · United States · https://www.acurxpharma.com
